Cost-effectiveness analysis of recombinant factor IX Fc fusion protein compared with recombinant factor IX for the treatment of moderate-severe to severe hemophilia B in China.
Pediatric blood & cancer（2023）
摘要
Compared with rFIX, rFIXFc appears to be a cost-effective option for the lifetime management of moderate-severe to severe HB patients in China.
更多查看译文
关键词
cost-effectiveness analysis,hemophilia B,recombinant factor IX,recombinant factor IX Fc fusion protein
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要